FSN Capital acquires Epista Life Sciences

FSN said that Epista has sales of DKK 119m (EUR 16m) in 2021 and has seen 30% annual growth since it was founded in 2009. 

CEO Klavs Esbjerg will retain a sizeable stake in the company. 

The company is an IT consultancy firm focused on compliance and business in life sciences. 

Buyer FSN said it will continue a buy-and-build strategy to build a pan-European provider in the niche life science IT services and consulting market. 

The company has already acquired Swedish peer Bruun & Maté. 

FSN added that the company will benefit from strong underlying market growth supported by the digitalisation of the life science industry and growing regulatory requirements within IT and automation. 

The GP is currently deploying capital via FSN Capital VI, which closed in August 2020 at EUR 1.8bn. 

Advisors 

FSN Capital - Deloitte (M&A); Plesner (legal); Frank Partners (CDD).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• Buyouts
• Nordics
• GPs
• FSN Capital
• Denmark